- Abarelix
drugbox
IUPAC_name = acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide
width = 400
CAS_number = 183552-38-7
ATC_prefix = L02
ATC_suffix = BX01
ATC_supplemental =
PubChem = 16131215
DrugBank = BTD00051
C=72 | H=95 | O=14 | N=14 | Cl=1
molecular_weight = 1416.06 g/mol
bioavailability =
protein_bound = 96–99%
metabolism =
elimination_half-life =
pregnancy_category =
legal_status =
routes_of_administration =Abarelix is an injectable
gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used inoncology to reduce the amount oftestosterone made in patients with advanced symptomaticprostate cancer for which no other treatment options are available. It belongs to the family of drugs calledGonadotropin-releasing hormone antagonist s.It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.
More information can be found at Plenaxis.de [http://www.Plenaxis.de] and FastProstateControl.com [http://www.FastProstateControl.com] .
Wikimedia Foundation. 2010.